Advertisement Interim Report January 1 - December 31, 2013 - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
More info about

Interim Report January 1 – December 31, 2013

Period: January 1 – December 31, 2013

  • Net sales SEK 294.1m (SEK 201.2m, pro forma SEK 312.4m)
  • System revenue SEK 197.1m (SEK 142.9m, pro forma SEK 200.2m)
  • EBITDA SEK 64.6m (SEK 57.7m, pro forma SEK 72.7m)
  • EBITDA margin 22.0 % (28.7%, pro forma 23.3%)
  • EBIT SEK 27.3m (SEK 28.6m)
  • Net profit SEK 15.8m (SEK 13.7m)
  • EPS before dilution SEK 0.30 (SEK 0.36)
  • Cash flow from operating activities SEK 74.6m (SEK 34.4m)

Period: October 1 – December 31, 2013

  • Net sales SEK 84.1m (SEK 87,3 m)
  • System revenue SEK 54.9 m (SEK 53.9 m)
  • EBITDA SEK 20.5m (SEK 27.2m)
  • EBITDA margin 24.4% (31.2%)
  • EBIT 10.7m (SEK 18.1m)
  • Net profit SEK 8.5m (SEK 8.6m)
  • EPS before dilution SEK 0.17 (SEK 0.17)
  • Cash flow from operating activities SEK 34.1m (SEK 20.1m)

For the full report, click here.

For additional information, contact:
Christian Sundin, CEO of Formpipe
Phone: +46 705 67 73 85